Three former Blue Sky directors who were originally named in a shareholder class action against the collapsed fund manager might be “dragged back” into the case after its chief operating officer pointed the finger at him in his defence, a court has heard.
A judge has railed against late submissions in a lawsuit by Super Retail Group’s former chief legal officer, calling the tardiness “inconceivable” after he “bent over backwards” to expedite the proceedings in an effort to curb costs.
An ex-worker at DVD manufacturer Technicolor has won more time to bring claims against her former employer, with a judge finding her 10-year delay was the result of potentially negligence by Nowicki Carbone and Maurice Blackburn.
AUSTRAC has taken The Star to task for making statements that are inconsistent with admissions the casino has made in the regulator’s case over its alleged failure to comply with its money laundering obligations.
The High Court has rejected a liquidator’s appeal arguing that two NSW printing press companies’ joint right to sue could be pooled to pay off debts for the entire corporate group.
A $100 million settlement by AMP in a class action by financial planners over the wealth manager’s buyer of last resort policy has been given the OK, but the litigation funder won’t be reimbursed for $2.6 million in insurance and administrative costs.
Boral’s former CEO Michael Kane can be questioned at trial over a reference he made in an email to findings by EY about the building material group’s poor performing US windows business, despite claims that the findings were privileged.
A long-time client of a former Holding Redlich partner has been granted a permanent injunction restraining the lawyer from acting against it in proceedings over a Queensland residential development.
Axed Seven Network reporter Robert Ovadia has dropped a lawsuit against his former boss, just days after the court heard that 13 women came forward with complaints following his dismissal.
Mesoblast has agreed to settle a shareholder class action centred on statements to the market about its Remestemcel-L treatment, resolving claims it misrepresented the efficacy of the therapy for COVID-19 patients.